Complexation and Sequestration of BMP-2 from an ECM Mimetic Hyaluronan Gel for Improved Bone Formation

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Kisiel, Marta ^a,g   Klar, Agnieszka S ^b   Ventura, Manuela ^c   Buijs, Jos ^a,d   Mafina, Marc Krystelle ^e   Cool, Simon M ^f   Hilborn, Jöns ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d GE HEALTHCARE   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^g Medical Center Hospital in Enköping   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN; HYALURONIC ACID; BMP2 PROTEIN, RAT; IMMOBILIZED PROTEIN; IMMUNOLOGICAL ADJUVANT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BINDING AFFINITY; BINDING KINETICS; BIOLOGICAL ACTIVITY; BONE MASS; BONE MINERAL; BONE STRUCTURE; COMPLEX FORMATION; CONTROLLED STUDY; COVALENT BOND; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; PROTEIN METABOLISM; PROTEIN SECRETION; PROTEIN STABILITY; RAT; SCANNING ELECTRON MICROSCOPY; SURFACE PLASMON RESONANCE; ANIMAL; BONE DEVELOPMENT; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; SPRAGUE DAWLEY RAT; TIME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CELLS, CULTURED; HUMANS; HYALURONIC ACID; IMMOBILIZED PROTEINS; MALE; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84885977795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078551     Document Type: Article

References (59)

1. Heiple KG, Chase SW, Herndon CH, (1963) A Comparative Study of the Healing Process Following Different Types of Bone Transplantation. J Bone Joint Surg Am 45: 1593-1616. PubMed: 14083136.
2. Younger EM, Chapman MW, (1989) Morbidity at bone graft donor sites. J Orthop Trauma 3: 192-195. doi:10.1097/00005131-198909000-00002. PubMed: 2809818.
3. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, et al. (2003) Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A: 1544-1552. PubMed: 12925636.
4. Okubo Y, Bessho K, Fujimura K, Iizuka T, Miyatake SI, (2000) Osteoinduction by bone morphogenetic protein-2 via adenoviral vector under transient immunosuppression. Biochem Biophys Res Commun 267: 382-387. doi:10.1006/bbrc.1999.1975. PubMed: 10623628.
5. Kusumoto K, Bessho K, Fujimura K, Akioka J, Ogawa Y, et al. (1998) Prefabricated muscle flap including bone induced by recombinant human bone morphogenetic protein-2: an experimental study of ectopic osteoinduction in a rat latissimus dorsi muscle flap. Br J Plast Surg 51: 275-280. doi:10.1054/bjps.1998.0008. PubMed: 9771344.
6. Uludag H, D'Augusta D, Golden J, Li J, Timony G, et al. (2000) Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: A correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J Biomed Mater Res 50: 227-238. doi:10.1002/(SICI)1097-4636(200005)50:2. PubMed: 10679688.
7. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, et al. (1988) Novel regulators of bone formation: molecular clones and activities. Science 242: 1528-1534. doi:10.1126/science.3201241. PubMed: 3201241.
8. Caetano-Lopes J, Lopes A, Rodrigues A, Fernandes D, Perpétuo IP, et al. (2011) Upregulation of Inflammatory Genes and Downregulation of Sclerostin Gene Expression Are Key Elements in the Early Phase of Fragility Fracture Healing. PLOS ONE 6: e16947. PubMed: 21347301.
9. Zhao B, Katagiri T, Toyoda H, Takada T, Yanai T, et al. (2006) Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 281: 23246-23253. doi:10.1074/jbc.M511039200. PubMed: 16754660.
10. Govender S, Vadasz P, (2002) Weak non-linear analysis of moderate Stefan number stationary convection in rotating mushy layers. Transp Porous Media 49: 247-263. doi:10.1023/A:1016241225343.
11. Berner A, Reichert JC, Müller MB, Zellner J, Pfeifer C, et al. (2012) Treatment of long bone defects and non-unions: from research to clinical practice. Cell Tissue Res 347: 501-519. doi:10.1007/s00441-011-1184-8. PubMed: 21574059.
12. Shields LBE, Raque GH, Glassman SD, Campbell M, Vitaz T, et al. (2006) Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 31: 542-547. doi:10.1097/01.brs.0000201424.27509.72. PubMed: 16508549.
13. Neovius E, Lemberger M, Docherty Skogh AC, Hilborn J, Engstrand T, (2012) Alveolar bone healing accompanied by severe swelling in cleft children treated with bone morphogenetic protein-2 delivered by hydrogel. J Plast Reconstr Aesthet Surg, 66: 37-42. PubMed: 22980542.
14. Friess W, Uludag H, Foskett S, Biron R, Sargeant C, (1999) Characterization of absorbable collagen sponges as rhBMP-2 carriers. Int J Pharm 187: 91-99. doi:10.1016/S0378-5173(99)00174-X. PubMed: 10502616.
15. Carragee EJ, Hurwitz EL, Weiner BK,. (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11: 471-491. doi:10.1016/j.spinee.2011.04.023. PubMed: 21729796.
16. Fu YC, Nie H, Ho ML, Wang CK, Wang CH, (2008) Optimized bone regeneration based on sustained release from three-dimensional fibrous PLGA/HAp composite scaffolds loaded with BMP-2. Biotechnol Bioeng 99: 996-1006. doi:10.1002/bit.21648. PubMed: 17879301.
17. Sawyer AA, Song SJ, Susanto E, Chuan P, Lam CX, et al. (2009) The stimulation of healing within a rat calvarial defect by mPCL-TCP/collagen scaffolds loaded with rhBMP-2. Biomaterials 30: 2479-2488. doi:10.1016/j.biomaterials.2008.12.055. PubMed: 19162318.
18. Jeon O, Song SJ, Yang HS, Bhang SH, Kang SW, et al. (2008) Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. Biochem Biophys Res Commun 369: 774-780. doi:10.1016/j.bbrc.2008.02.099. PubMed: 18313401.
19. Yang HS, La WG, Bhang SH, Jeon JY, Lee JH, et al. (2010) Heparin-Conjugated Fibrin as an Injectable System for Sustained Delivery of Bone Morphogenetic Protein-2. Tissue Eng A 16: 1225-1233. doi:10.1089/ten.tea.2009.0390. PubMed: 19886733.
20. Kisiel M, Ventura M, Oommen OP, George A, Walboomers XF, et al. (2012) Critical assessment of rhBMP-2 mediated bone induction: An in vitro and in vivo evaluation. J Control Release 162: 646-653. doi:10.1016/j.jconrel.2012.08.004. PubMed: 22902595.
21. Martínez-Sanz E, Varghese OP, Kisiel M, Engstrand T, Reich KM, et al. (2012) Minimally invasive mandibular bone augmentation using injectable hydrogels. J Tissue Eng Regen Med, 6 (Suppl 3):: s15-23. PubMed: 22941759.
22. Patterson J, Siew R, Herring SW, Lin AS, Guldberg R, et al. (2010) Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration. Biomaterials 31: 6772-6781. doi:10.1016/j.biomaterials.2010.05.047. PubMed: 20573393.
23. Kisiel M, Klar AS, Martino MM, Ventura M, Hilborn J, (2013) Evaluation of injectable constructs for bone repair with a subperiosteal cranial model in the rat. PLOS ONE 8: e71683. doi:10.1371/journal.pone.0071683. PubMed: 23967235.
24. Toole BP, (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539. doi:10.1038/nrc1391. PubMed: 15229478.
25. Schiller J, Fuchs B, Arnhold J, Arnold K, (2003) Contribution of reactive oxygen species to cartilage degradation in rheumatic diseases: molecular pathways, diagnosis and potential therapeutic strategies. Curr Med Chem 10: 2123-2145. doi:10.2174/0929867033456828. PubMed: 12871089.
26. Csoka AB, Frost GI, Stern R, (2001) The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 20: 499-508. doi:10.1016/S0945-053X(01)00172-X. PubMed: 11731267.
27. Lepperdinger G, Müllegger J, Kreil G, (2001) Hyal2--less active, but more versatile? Matrix Biol 20: 509-514. doi:10.1016/S0945-053X(01)00170-6. PubMed: 11731268.
28. Bergman K, Engstrand T, Hilborn J, Ossipov D, Piskounova S, et al. (2009) Injectable cell-free template for bone-tissue formation. J Biomed Mater Res A 91A: 1111-1118. doi:10.1002/jbm.a.32289. PubMed: 19107794.
29. Kisiel M, Martino MM, Ventura M, Hubbell JA, Hilborn J, et al. (2012) Improving the osteogenic potential of BMP-2 with hyaluronic acid hydrogel modified with integrin-specific fibronectin fragment. Biomaterials, 34: 704-12. PubMed: 23103154.
30. Nageeb M, Nouh SR, Bergman K, Nagy NB, Khamis D, et al. (2012) Bone Engineering by Biomimetic Injectable Hydrogel. Mol Cryst Liq Cryst 555: 177-188. doi:10.1080/15421406.2012.635530.
31. Liu HW, Chen CH, Tsai CL, Lin IH, Hsiue GH, (2007) Heterobifunctional poly(ethylene glycol)-tethered bone morphogenetic protein-2-stimulated bone marrow mesenchymal stromal cell differentiation and osteogenesis. Tissue Eng 13: 1113-1124. doi:10.1089/ten.2006.0209. PubMed: 17355208.
32. Jha AK, Yang W, Kirn-Safran CB, Farach-Carson MC, Jia X, (2009) Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 30: 6964-6975. doi:10.1016/j.biomaterials.2009.09.009. PubMed: 19775743.
33. Jeon O, Song SJ, Kang SW, Putnam AJ, Kim BS, (2007) Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials 28: 2763-2771. doi:10.1016/j.biomaterials.2007.02.023. PubMed: 17350678.
34. Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, et al. (2003) Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 278: 43229-43235. doi:10.1074/jbc.M300937200. PubMed: 12912996.
35. Lyon M, Deakin JA, Rahmoune H, Fernig DG, Nakamura T, et al. (1998) Hepatocyte growth factor scatter factor binds with high affinity to dermatan sulfate. J Biol Chem 273: 271-278. doi:10.1074/jbc.273.1.271. PubMed: 9417075.
36. Koźma EM, Wisowski G, Olczyk K, (2009) Platelet derived growth factor BB is a ligand for dermatan sulfate chain(s) of small matrix proteoglycans from normal and fibrosis affected fascia. Biochimie 91: 1394-1404. doi:10.1016/j.biochi.2009.07.010. PubMed: 19631712.
37. Johnson MR, Boerckel JD, Dupont KM, Guldberg RE, (2011) Functional restoration of critically sized segmental defects with bone morphogenetic protein-2 and heparin treatment. Clin Orthop Relat Res 469: 3111-3117. doi:10.1007/s11999-011-2012-x. PubMed: 21863396.
38. Bramono DS, Murali S, Rai B, Ling L, Poh WT, et al. (2012) Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2). Bone 50: 954-964. doi:10.1016/j.bone.2011.12.013. PubMed: 22227436.
39. Piskounova S, Gedda L, Hulsart-Billström G, Hilborn J, Bowden T, (2012) Characterization of recombinant human bone morphogenetic protein-2 delivery from injectable hyaluronan-based hydrogels by means of (125) I-radiolabelling. J Tissue Eng Regen Med. PubMed: 22927307.
40. Santos MI, Reis RL, (2010) Vascularization in bone tissue engineering: physiology, current strategies, major hurdles and future challenges. Macromol Biosci 10: 12-27. doi:10.1002/mabi.200900107. PubMed: 19688722.
41. Traktuev DO, Prater DN, Merfeld-Clauss S, Sanjeevaiah AR, Saadatzadeh MR, et al. (2009) Robust Functional Vascular Network Formation in Vivo by Cooperation of Adipose Progenitor and Endothelial Cells. Circ Res 104: 1410-U1320. doi:10.1161/CIRCRESAHA.108.190926. PubMed: 19443841.
42. Ruppert R, Hoffmann E, Sebald W, (1996) Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 237: 295-302. doi:10.1111/j.1432-1033.1996.0295n.x. PubMed: 8620887.
43. Massagué J, (1990) The transforming growth factor-beta family. Annu Rev Cell Biol 6: 597-641. doi:10.1146/annurev.cb.06.110190.003121. PubMed: 2177343.
44. Xu X, Jha AK, Duncan RL, Jia X, (2011) Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2. Acta Biomaterialia 7: 3050-3059. doi:10.1016/j.actbio.2011.04.018. PubMed: 21550426.
45. Jiao X, Billings PC, O'Connell MP, Kaplan FS, Shore EM, et al. (2007) Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 282: 1080-1086. PubMed: 17020882.
46. Bhakta G, Rai B, Lim ZXH, Hui JH, Stein GS, et al. (2012) Hyaluronic acid-based hydrogels functionalized with heparin that support controlled release of bioactive BMP-2. Biomaterials 33: 6113-6122. doi:10.1016/j.biomaterials.2012.05.030. PubMed: 22687758.
47. Jones G, Sambrook PN, (1994) Drug-induced disorders of bone metabolism. Incidence, management and avoidance. Drug Saf 10: 480-489. doi:10.2165/00002018-199410060-00006. PubMed: 7917076.
48. Wolinsky-Friedland M, (1995) Drug-induced metabolic bone disease. Endocrinol Metab Clin North Am 24: 395-420. PubMed: 7656896.
49. Manton KJ, Leong DF, Cool SM, Nurcombe V, (2007) Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways. Stem Cells 25: 2845-2854. doi:10.1634/stemcells.2007-0065. PubMed: 17702986.
50. Trowbridge JM, Rudisill JA, Ron D, Gallo RL, (2002) Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7). J Biol Chem 277: 42815-42820. doi:10.1074/jbc.M204959200. PubMed: 12215437.
51. Osses N, Gutierrez J, Lopez-Rovira T, Ventura F, Brandan E, (2006) Sulfation is required for bone morphogenetic protein 2-dependent Id1 induction. Biochem Biophys Res Commun 344: 1207-1215. doi:10.1016/j.bbrc.2006.04.029. PubMed: 16647687.
52. Radek KA, Taylor KR, Gallo RL, (2009) FGF-10 and specific structural elements of dermatan sulfate size and sulfation promote maximal keratinocyte migration and cellular proliferation. Wound Repair Regen 17: 118-126. doi:10.1111/j.1524-475X.2008.00449.x. PubMed: 19152659.
53. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn CM, et al. (1995) FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science 268: 432-436. doi:10.1126/science.7536345. PubMed: 7536345.
54. Barger-Lux MJ, Recker RR, (2002) Bone microstructure in osteoporosis: transilial biopsy and histomorphometry. Top Magn Reson Imaging 13: 297-305. doi:10.1097/00002142-200210000-00002. PubMed: 12464743.
55. Peacock M, (2010) Calcium metabolism in health and disease. Clin J Am Soc Nephrol 5 (Suppl 1):: S23-S30. doi:10.2215/CJN.05910809. PubMed: 20089499.
56. Afonso L, Bandaru H, Rathod A, Badheka A, Ali Kizilbash M, et al. (2011) Prevalence, determinants, and clinical significance of cardiac troponin-I elevation in individuals admitted for a hypertensive emergency. J Clin Hypertens (Greenwich) 13: 551-556. doi:10.1111/j.1751-7176.2011.00476.x. PubMed: 21806764.
57. Chao EYS, Inoue N, Elias JJ, Aro H, (1998) Enhancement of fracture healing by mechanical and surgical intervention. Clin Orthop Relat Res: pp. S163-S178. PubMed: 9917637.
58. Clarke B, (2008) Normal Bone Anatomy and Physiology. Clin J Am Soc Nephrol 3: S131-S139. doi:10.2215/CJN.04151206. PubMed: 18988698.
59. Laub M, Seul T, Schmachtenberg E, Jennissen HP, (2001) Molecular modelling of bone morphogenetic protein-2 (BMP-2) by 3D-rapid prototyping. Materialwiss Werkstofftech 32: 926-930. doi:10.1002/1521-4052(200112)32:12.